Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Rang in aandelen #15446
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Aandeelprijs
$9.42
Marktkapitalisatie
$354.69M
Verandering (1 dag)
-0.83%
Verandering (1 jaar)
91.09%
Land
US
Handel BioAge Labs Inc. (BIOA)

Categorie

Aandelsplitsingen voor BioAge Labs Inc. (BIOA)
Het aandeel BioAge Labs Inc. (symbool: BIOA) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Sep 01, 2026.
Eén aandeel BIOA dat vóór Sep 01, 2026 werd gekocht, staat nu gelijk aan 0 aandelen BIOA.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH